Summary:
- Valneva, a specialty vaccine company, has reported its full-year 2022 results and provided business updates and outlook for 2023.
- The company's total revenues in 2022 were €579.4 million, with product sales of €487.8 million, representing a 94% increase compared to 2021.
- Valneva is focused on advancing its vaccine candidates, including its COVID-19 vaccine VLA2001, which received conditional marketing authorization in the European Union and the United Kingdom, and its Lyme disease vaccine candidate VLA15, which is currently in Phase 3 clinical trials.